This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Diabetes care, 39(7), 1241-9
Citation
Kazda, Christof M; Ding, Ying; Kelly, Ronan P; Garhyan, Parag; Shi, Chunxue; Lim, Chay Ngee; Fu, Haoda; Watson, David E; Lewin, Andrew J; Landschulz, William H; Deeg, Mark A; Moller, David E; Hardy, Thomas A. (2016). Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.. Diabetes care, 39(7), 1241-9. https://doi.org/10.2337/dc15-1643